Publication date: Jun 23, 2025
During the COVID-19 pandemic, many clinical trials were conducted to identify effective COVID-19 therapeutics. However, while a large amount of resources was invested and significant numbers of patients participated, this did not necessarily have an impact on clinical practice. To face these issues, initiatives such as the 100 Days Mission have been set out globally. Yet, limited data exist on the context surrounding the implementation of clinical trials at a national level during a health emergency. The study explored experiences and perceptions of principal investigators in conducting clinical trials for COVID-19 therapeutics in Japan. A qualitative study was conducted using semistructured interviews. The obtained data were inductively analysed using thematic analysis. We interviewed 15 principal investigators between September and November 2022 who conducted investigator-initiated clinical trials on the development of COVID-19 therapeutics in Japan. Three themes were generated: structural barriers, fragmented efforts and limited evidence generation. Structural barriers and fragmented efforts comprised four subthemes: individual, institutional, interinstitutional and policy/regulatory levels. Structural barriers at all levels included (1) limitations of individual capabilities, (2) the double burden of clinical practice and research, (3) inefficient interinstitutional collaboration and (4) regulatory frameworks and available resources that interrupt stakeholders’ actions, leading to limited evidence generation despite the fragmented efforts of principal investigators and other stakeholders. This study illustrated that the efforts of Japanese principal investigators did not necessarily pay off in identifying therapeutics. A strategic and systematic approach for an improved national clinical trial ecosystem must be sought during the interpandemic period to overcome structural barriers in harmonisation with the global stakeholders.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | emergency |
| disease | MESH | tics |
| disease | IDO | country |
| drug | DRUGBANK | Indoleacetic acid |
| disease | IDO | process |
| disease | MESH | causality |
| disease | MESH | infectious diseases |
| drug | DRUGBANK | Etoperidone |
| drug | DRUGBANK | Trestolone |
| drug | DRUGBANK | Iron |
| disease | MESH | non communicable diseases |
| drug | DRUGBANK | Methionine |
| disease | IDO | quality |
| pathway | REACTOME | Infectious disease |
| disease | IDO | infectious disease |
| disease | MESH | coronavirus infection |
| disease | MESH | critical illness |
| drug | DRUGBANK | Favipiravir |
| pathway | REACTOME | Translation |
| disease | MESH | sepsis |
| disease | MESH | Pneumonia |
| drug | DRUGBANK | Oxygen |
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | influenza |